Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences Inc RCUS
News
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
Arcus Biosciences Announces New Employment Inducement Grants
Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial
Arcus Biosciences Discontinues Lung Cancer Trial With Gilead
Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment — Update
Arcus Biosciences to Discontinue Phase 3 Trial of Potential Cancer Treatment
United States